Agreement Limiting Wize Pharma's Commercialization Rights of LO2A in China – Resdevco Ltd. and Wize Pharma Ltd. (September 25, 2017)
Resdevco Ltd. and Wize Pharma Ltd. have agreed that Wize Pharma's exclusive right to commercialize LO2A eye drops in China will last for only one year unless Wize Pharma signs a distribution agreement for LO2A in China by September 6, 2018. If no such agreement is signed by that date, Wize Pharma's commercialization rights in China will end. This agreement is signed by both parties and sets a clear deadline for Wize Pharma to secure distribution in China.
Exhibit 10.42
RESDEVCO LTD.
Commercialization Rights of LO2A in China
Resdevco Ltd. and Wize Pharma Ltd. hereby agree that Wize Pharma’s sole rights to commercialize LO2A in China, as declared in the letter from Resdevco, dated, September 6, 2017, shall be limited to one year if by September 6, 2018, Wize Pharma has not signed a distribution agreement of LO2A eye drops in China.
| /s/ Prof. S. Dikstein | September 25, 2017 | |
| Resdevco Ltd | Date | |
| /s/ Wize Pharma Ltd. | September 25, 2017 | |
| Wize Pharma Ltd. | Date |
P.O.B. 3338, Jerusalem, Israel
Tel. and Fax: 972-2 ###-###-####
